<DOC>
	<DOCNO>NCT00091624</DOCNO>
	<brief_summary>A Phase I Study CC-5013 combination Doxil , Vincristine Decadron ( DVd ) Subjects Relapsed Refractory Multiple Myeloma</brief_summary>
	<brief_title>A Study Doxil , Vincristine Decadron ( DVd ) +/ CC-5013 Relapsed Refractory Multiple Myeloma ( MM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Age great 18 year time signing informed consent form . Able adhere study visit schedule protocol requirement . Diagnosed active multiple myeloma consider disease progression least 2 cycle antimyeloma treatment relapse progressive disease treatment . Measurable myeloma paraprotein level serum ( ≥ 0.5g/dL ) urine ( ≥ 0.2 g excrete 24hour collection sample ) . Eastern Cooperative Group ( ECOG ) Performance Status 02 . Performance status 3 4 allow related bony disease . Bilirubin &lt; 2 x upper limit normal ( ULN ) . Liver enzymes ( ALT AST ) &lt; 3 x ULN . Must adequate bone marrow function : * Absolute neutrophil count &gt; 1,000 cells/mm3 ( 1.0 x 109/L ) * Platelets ≥ 100,000 cells/mm3 ( 100 x 109/L ) * Hemoglobin ≥ 8 g/dL Must adequate renal function : creatinine ≤ 2.5 mg/dL . Must 2d echocardiogram indicate LVEF ≥ 50 % within 42 day prior first dose study drug . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug . Severe infection require intravenous antibiotic treatment . Life expectancy le 3 month . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer subject diseasefree least 5 year . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia . Subjects receive &gt; 500mg/m2 doxorubicin alone , Doxil® alone , doxorubicin plus Doxil® . Prior treatment CC5013 . Prior development ≥ grade 2 ( NCI CTC ) allergic reaction/hypersensitivity take thalidomide . Prior development ≥ grade 3 ( NCI CTC ) rash desquamation take thalidomide . History cardiac disease , New York Heart Association Class II great . Uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia ) , pulmonary , hepatic renal disease unless renal insufficiency felt secondary multiple myeloma . Any investigational agent systemic antimyeloma therapy within 28 day first dose treatment . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CC-5013</keyword>
	<keyword>CC5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>